This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Multiple Sclerosis/ Demyelinating Disease  • Radiologic Imaging  • Magnetic Resonance Imaging  • Immunologic Disorders  • Alert me on articles by topic

Advancement in Linking the Pictures With the Progression

Arch Neurol. 2001;58:35-36.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MAGNETIC RESONANCE (MR) imaging (MRI) is currently the best paraclinical tool for the diagnosis of multiple sclerosis (MS). Conventional spin-echo images of the brain are routinely used in clinical practice because of their high sensitivity in the detection of lesions of MS. The burden of disease as measured by T2 lesion volume has been used as a quantitative outcome measure in several recent phase 3 MS clinical trials. Interestingly, although MS plaques detected on postmortem examination colocalize with T2 lesions, there is a weak correlation between T2 disease burden and clinical disability. The reason for this poor correlation is not clear. However, one possibility is that the pathologic processes being represented by T2-weighted lesions of the brain are quite diverse. Inflammation, demyelination, edema, gliosis, and axonal loss are all processes that can be represented by T2-weighted images of the MS brain, yet only axonal loss and chronic demyelination would be . . . [Full Text of this Article]

RELATED ARTICLE

Enhancing Magnetic Resonance Imaging Lesions and Cerebral Atrophy in Patients With Relapsing Multiple Sclerosis
T. P. Leist, M. I. Gobbini, J. A. Frank, and H. F. McFarland
Arch Neurol. 2001;58(1):57-60.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Contrasting Roles for Axonal Degeneration in an Autoimmune versus Viral Model of Multiple Sclerosis: When Can Axonal Injury Be Beneficial?
Tsunoda et al.
Am. J. Pathol. 2007;170:214-226.
ABSTRACT | FULL TEXT  

A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis
Walker et al.
Mult Scler 2005;11:149-158.
ABSTRACT  

Effect of drugs in secondary disease progression in patients with multiple sclerosis
Kappos
Mult Scler 2004;10:S46-S55.
ABSTRACT  

Effect of drugs in secondary disease progression in patients with multiple sclerosis
Kappos
Mult Scler 2004;10:S46-S55.
ABSTRACT